122 related articles for article (PubMed ID: 11265777)
1. A prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of nystatin on the development of oral irritation in patients receiving high-dose intravenous interleukin-2.
Ohnmacht GA; Phan GQ; Mavroukakis SA; Steinberg SM; Shea YR; Witebsky FG; McIntyre LS; Goodwin RS; Muehlbauer PM; Morton KE; Rogers-Freezer LJ; Seipp CA; Rosenberg SA; Marincola FM
J Immunother; 2001; 24(2):188-92. PubMed ID: 11265777
[TBL] [Abstract][Full Text] [Related]
2. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.
Margolin K; Atkins M; Sparano J; Sosman J; Weiss G; Lotze M; Doroshow J; Mier J; O'Boyle K; Fisher R; Campbell E; Rubin J; Federighi D; Bursten S
Clin Cancer Res; 1997 Apr; 3(4):565-72. PubMed ID: 9815721
[TBL] [Abstract][Full Text] [Related]
3. Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial.
Hamza OJ; Matee MI; Brüggemann RJ; Moshi MJ; Simon EN; Mugusi F; Mikx FH; van der Lee HA; Verweij PE; van der Ven AJ
Clin Infect Dis; 2008 Nov; 47(10):1270-6. PubMed ID: 18840077
[TBL] [Abstract][Full Text] [Related]
4. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Sorge J; Sittl R
Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
[TBL] [Abstract][Full Text] [Related]
5. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.
Acquavella N; Kluger H; Rhee J; Farber L; Tara H; Ariyan S; Narayan D; Kelly W; Sznol M
J Immunother; 2008; 31(6):569-76. PubMed ID: 18528297
[TBL] [Abstract][Full Text] [Related]
6. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS
Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.
Clark JI; Atkins MB; Urba WJ; Creech S; Figlin RA; Dutcher JP; Flaherty L; Sosman JA; Logan TF; White R; Weiss GR; Redman BG; Tretter CP; McDermott D; Smith JW; Gordon MS; Margolin KA
J Clin Oncol; 2003 Aug; 21(16):3133-40. PubMed ID: 12810695
[TBL] [Abstract][Full Text] [Related]
10. Antifungal topical therapy in oral chronic candidosis. A comparative study.
Lopez-De-Blanc SA; Salati-De-Mugnolo N; Femopase FL; Benitez MB; Morelatto RA; Astrada-De-Verde L; Masih D
Med Oral; 2002; 7(4):260-70. PubMed ID: 12134127
[TBL] [Abstract][Full Text] [Related]
11. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
[TBL] [Abstract][Full Text] [Related]
12. IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial.
Atzpodien J; Kirchner H; Illiger HJ; Metzner B; Ukena D; Schott H; Funke PJ; Gramatzki M; Jürgenson S; Wandert T; Patzelt T; Reitz M
Br J Cancer; 2001 Oct; 85(8):1130-6. PubMed ID: 11710825
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Autier J; Escudier B; Wechsler J; Spatz A; Robert C
Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
[TBL] [Abstract][Full Text] [Related]
14. The treatment of oral candidiasis in a cohort of South African HIV/AIDS patients.
Blignaut E; Botes ME; Nieman HL
SADJ; 1999 Dec; 54(12):605-8. PubMed ID: 16892568
[TBL] [Abstract][Full Text] [Related]
15. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.
Mazlumzadeh M; Hunder GG; Easley KA; Calamia KT; Matteson EL; Griffing WL; Younge BR; Weyand CM; Goronzy JJ
Arthritis Rheum; 2006 Oct; 54(10):3310-8. PubMed ID: 17009270
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial comparing ketoconazole and nystatin prophylactic therapy in neutropenic patients.
Vogler WR; Malcom LG; Winton EF
Cancer Invest; 1987; 5(4):267-73. PubMed ID: 3664330
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
Ogrendik M
Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
[TBL] [Abstract][Full Text] [Related]
19. Effect of an antifungal denture liner on the saliva yeast count in patients with denture stomatitis: a pilot study.
Geerts GA; Stuhlinger ME; Basson NJ
J Oral Rehabil; 2008 Sep; 35(9):664-9. PubMed ID: 18793352
[TBL] [Abstract][Full Text] [Related]
20. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
